CORPORATE OVERVIEW AUGUST 2021 Frank Bedu-Addo Ph.D. President & CEO 6 Nasdaq: PDSB Developing powerful, safe, versatile immunotherapies Forward-Looking Statements | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

[Part I — Financial Information](index=4&type=section&id=Part%20I%20%E2%80%94%20Financial%20Information) [Financial Statements (Unaudited)](index=4&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) The company reported a net loss of $3.6 million for the six months ended June 30, 2021, a significant improvement from the $6.9 million loss in the same period of 2020, primarily due to a $4.5 million income tax benefit from the sale of New Jersey Net Operating Losses (NOLs) Total assets increased substantially to $77.4 million from $30.9 million at year-end 2020, driven by a significant increase in cash and cash equivalents from financing activities Stockholders' equity also saw strong growth to $73.0 million [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2021, total assets were $77.4 million, a significant increase from $30.9 million at December 31, 2020 This growth was primarily driven by a rise in cash and cash equivalents to $74.7 million from $28.8 million following successful financing activities Total liabilities remained relatively stable at $4.4 million, while total stockholders' equity grew substantially to $73.0 million from $27.1 million | | June 30, 2021 (unaudited) | December 31, 2020 | |:---|:---:|:---:| | **Assets** | | | | Cash and cash equivalents | $ 74,749,201 | $ 28,839,565 | | Total current assets | $ 76,934,390 | $ 30,337,230 | | Total assets | $ 77,390,726 | $ 30,890,379 | | **Liabilities and Stockholders' Equity** | | | | Total current liabilities | $ 4,002,818 | $ 3,270,450 | | Total Liabilities | $ 4,398,132 | $ 3,760,803 | | Total stockholders' equity | $ 72,992,594 | $ 27,129,576 | | Total liabilities and stockholders' equity | $ 77,390,726 | $ 30,890,379 | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) For the three months ended June 30, 2021, the company reported a net loss of $0.6 million, a significant reduction from a $2.9 million loss in Q2 2020 For the six-month period, the net loss was $3.6 million, down from $6.9 million year-over-year This improvement was largely due to a one-time $4.5 million income tax benefit in 2021 Operating expenses increased, with R&D expenses nearly doubling to $2.8 million in Q2 2021 from $1.4 million in Q2 2020, reflecting increased clinical trial activity | | Three Months Ended June 30, | Six Months Ended June 30, | |:---|:---:|:---:|:---:|:---:| | | **2021** | **2020** | **2021** | **2020** | | Research and development expenses | $ 2,764,195 | $ 1,414,225 | $ 4,177,252 | $ 3,385,904 | | General and administrative expenses | $ 2,341,828 | $ 1,521,736 | $ 3,978,044 | $ 3,581,884 | | Total operating expenses | $ 5,106,023 | $ 2,935,961 | $ 8,155,296 | $ 6,967,788 | | Loss from operations | $ (5,106,023) | $ (2,935,961) | $ (8,155,296) | $ (6,967,788) | | Benefit for income taxes | $ 4,516,488 | $ – | $ 4,516,488 | $ – | | Net loss and comprehensive loss | $ (588,931) | $ (2,929,344) | $ (3,637,549) | $ (6,914,752) | | Net loss per share, basic and diluted | $ (0.03) | $ (0.19) | $ (0.16) | $ (0.54) | [Condensed Consolidated Statements of Changes in Stockholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Stockholders%27%20Equity) Stockholders' equity increased significantly to $73.0 million as of June 30, 2021, from $27.1 million at the end of 2020 This substantial growth was primarily driven by the issuance of common stock, which generated net proceeds of $48.5 million during the first six months of 2021 The increase was partially offset by the net loss of $3.6 million for the same period - Total stockholders' equity grew from **$27.1 million** at the end of 2020 to **$73.0 million** as of June 30, 2021[17](index=17&type=chunk) - The increase was primarily due to **$48.5 million** in net proceeds from the issuance of common stock, partially offset by a **$3.6 million** net loss[17](index=17&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For the six months ended June 30, 2021, net cash used in operating activities was $2.9 million, a significant decrease from $7.3 million in the prior-year period, largely due to a $4.5 million NOL sale Net cash provided by financing activities was $48.8 million, primarily from a public offering of common stock This resulted in a net increase in cash of $45.9 million, boosting the end-of-period cash and cash equivalents balance to $74.7 million | | Six Months Ended June 30, | |:---|:---:|:---:| | | **2021** | **2020** | | Net cash used in operating activities | $ (2,855,966) | $ (7,267,705) | | Net cash provided by financing activities | $ 48,765,601 | $ 12,040,461 | | Net increase in cash and cash equivalents | $ 45,909,635 | $ 4,772,756 | | Cash and cash equivalents at end of period | $ 74,749,200 | $ 16,934,495 | [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes detail the company's operations as a clinical-stage immunotherapy company, highlighting the impact of COVID-19 on clinical trial timelines Key financial events include raising approximately $48.5 million net from a public offering in June 2021 and receiving a $4.5 million tax benefit from selling New Jersey NOLs in May 2021 The company faces a shareholder lawsuit filed in July 2021 concerning its equity incentive plan Management asserts that its cash balance of $74.7 million is sufficient to fund operations for at least the next 12 months - The company is a clinical-stage immunotherapy company developing cancer and infectious disease treatments based on its proprietary Versamune® T-cell activating platform[23](index=23&type=chunk) - The COVID-19 pandemic has caused delays in clinical trial enrollment for PDS0101, though all three studies have been initiated[25](index=25&type=chunk) - In June 2021, the company completed a public offering, raising net proceeds of approximately **$48.5 million**[46](index=46&type=chunk) - In May 2021, the company sold New Jersey NOL carryforwards, resulting in a **$4.5 million** income tax benefit[45](index=45&type=chunk)[68](index=68&type=chunk) - A shareholder lawsuit was filed on July 23, 2021, challenging the approval of the Restated 2014 Equity Incentive Plan and subsequent option grants[73](index=73&type=chunk) - Based on available cash of **$74.7 million**, management believes there are sufficient funds for at least 12 months of operations from the report's filing date[40](index=40&type=chunk)[48](index=48&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=18&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section provides an overview of the company's clinical-stage pipeline, centered on the Versamune® platform and its lead candidate, PDS0101, which is in multiple Phase 2 trials It details the results of operations, showing increased R&D and G&A expenses driven by advancing clinical programs and higher personnel costs The discussion on liquidity highlights successful capital raises, including a $48.5 million net offering in June 2021 and a $4.5 million NOL sale Management believes this provides sufficient capital for at least the next 12 months The impact of COVID-19 on trial enrollment is also noted as a continuing challenge - The company's lead candidate, PDS0101, is being evaluated in three Phase 2 clinical trials for HPV-associated cancers, including in combination with Merck's KEYTRUDA®[84](index=84&type=chunk)[88](index=88&type=chunk)[92](index=92&type=chunk) - Interim data from an NCI-led trial of PDS0101 in a triple combination therapy showed high objective response rates in both checkpoint inhibitor naïve (**83%**) and refractory (**42%**) patients[89](index=89&type=chunk)[90](index=90&type=chunk) - As of June 30, 2021, the company had **$74.7 million** in cash and cash equivalents, which is deemed sufficient to fund operations for at least the next 12 months[103](index=103&type=chunk)[124](index=124&type=chunk) [Company Overview](index=19&type=section&id=Company%20Overview) PDS is a clinical-stage immunotherapy company developing treatments for cancer and infectious diseases using its proprietary Versamune® T-cell activating platform The lead product, PDS0101, is in three Phase 2 trials for HPV-associated cancers, including combinations with KEYTRUDA® and other agents Interim data from a trial with the NCI showed high objective response rates The pipeline also includes candidates for prostate, breast, and colorectal cancers (PDS0102, PDS0103), melanoma (PDS0104), and infectious diseases like influenza (PDS0202) and COVID-19 (PDS0203) - The VERSATILE-002 Phase 2 trial is evaluating PDS0101 with KEYTRUDA® for first-line treatment of HPV16-positive head and neck cancer Preliminary data is expected between Q4 2021 and Q1 2022[84](index=84&type=chunk)[87](index=87&type=chunk) - An NCI-led Phase 2 trial of PDS0101 in combination with Bintrafusp alfa and NHS-IL12 showed an **83%** objective response rate in CPI naïve patients and **42%** in CPI refractory patients in interim data presented at ASCO 2021[88](index=88&type=chunk)[89](index=89&type=chunk)[90](index=90&type=chunk) - A Phase 2 trial with MD Anderson is evaluating PDS0101 with chemo-radiotherapy in locally advanced cervical cancer, with preliminary data expected in H1 2022[92](index=92&type=chunk) - The pipeline includes PDS0102 (prostate/breast cancer), PDS0103 (MUC1-associated cancers), PDS0104 (melanoma), and infectious disease vaccines for influenza (PDS0202) and COVID-19 (PDS0203)[93](index=93&type=chunk)[94](index=94&type=chunk)[95](index=95&type=chunk) [Results of Operations](index=23&type=section&id=Results%20of%20Operations) For Q2 2021, R&D expenses increased 95% year-over-year to $2.8 million, driven by higher clinical study and manufacturing costs G&A expenses rose 54% to $2.3 million due to increased personnel and professional fees For the first six months of 2021, R&D expenses grew 23% to $4.2 million, and G&A expenses increased 11% to $4.0 million A significant $4.5 million income tax benefit from an NOL sale substantially reduced the net loss for both the quarter and six-month period compared to the prior year | | Three Months Ended June 30, | Increase (Decrease) | |:---|:---:|:---:|:---:| | | **2021** | **2020** | **%** | | Research and development expenses | $ 2,764,000 | $ 1,414,000 | 95% | | General and administrative expenses | $ 2,342,000 | $ 1,522,000 | 54% | | Net loss and comprehensive loss | $ (589,000) | $ (2,929,000) | (80)% | | | Six Months Ended June 30, | Increase (Decrease) | |:---|:---:|:---:|:---:| | | **2021** | **2020** | **%** | | Research and development expenses | $ 4,177,000 | $ 3,386,000 | 23% | | General and administrative expenses | $ 3,978,000 | $ 3,582,000 | 11% | | Net loss and comprehensive loss | $ (3,638,000) | $ (6,915,000) | (47)% | - The increase in R&D expenses for Q2 2021 was primarily due to a **$1.0 million** increase in clinical studies and **$0.1 million** in manufacturing costs[110](index=110&type=chunk) - A **$4.5 million** income tax benefit was recognized from the sale of New Jersey Net Operating Losses (NOLs), significantly reducing the net loss[112](index=112&type=chunk)[116](index=116&type=chunk) [Liquidity and Capital Resources](index=25&type=section&id=Liquidity%20and%20Capital%20Resources) As of June 30, 2021, the company had a strong liquidity position with $74.7 million in cash and cash equivalents This was achieved through several financing activities, most notably a public offering in June 2021 that raised net proceeds of $48.5 million and a $4.5 million sale of NOLs in May 2021 Net cash used in operating activities for the first six months of 2021 was $2.9 million Management believes the existing cash reserves are sufficient to fund operations for at least the next 12 months - In June 2021, the company sold 6,088,235 shares of common stock, receiving net proceeds of approximately **$48.5 million**[121](index=121&type=chunk) - In May 2021, the company received approximately **$4.5 million** from the sale of New Jersey NOLs[122](index=122&type=chunk) - As of June 30, 2021, the company had **$74.7 million** in cash and cash equivalents[123](index=123&type=chunk) - Management believes existing cash will be sufficient to satisfy operating needs for at least one year from the filing date[124](index=124&type=chunk) | Cash Flows (in thousands) | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | |:---|:---:|:---:| | Net cash used in operating activities | $ (2,856) | $ (7,268) | | Net cash provided by financing activities | $ 48,766 | $ 12,040 | [Quantitative and Qualitative Disclosures About Market Risk](index=31&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risk exposure is interest rate sensitivity related to its $74.7 million in cash and cash equivalents These funds are held in a non-interest-bearing operating account and an institutional U.S. Treasury money market fund Due to the short-term nature and low-risk profile of these investments, management does not believe a 100 basis point change in interest rates would materially affect their fair market value - The company's primary market risk is interest rate sensitivity on its **$74.7 million** in cash and cash equivalents[147](index=147&type=chunk) - Due to the short-term, low-risk nature of investments (U.S. Treasury money market fund), a significant change in interest rates is not expected to have a material impact[147](index=147&type=chunk) [Controls and Procedures](index=31&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including the CEO and CFO, conducted an evaluation of the company's disclosure controls and procedures as of June 30, 2021 They concluded that these controls are effective Furthermore, no changes in internal control over financial reporting occurred during the quarter that have materially affected, or are reasonably likely to materially affect, these controls - Management concluded that disclosure controls and procedures were effective as of the end of the quarter covered by the report[148](index=148&type=chunk) - No material changes to internal control over financial reporting were identified during the quarter[149](index=149&type=chunk) [Part II — Other Information](index=32&type=section&id=Part%20II%20%E2%80%94%20Other%20Information) [Legal Proceedings](index=32&type=section&id=Item%201.%20Legal%20Proceedings) On July 23, 2021, a purported stockholder filed a class action and derivative lawsuit against PDS, its directors, and certain executive officers The complaint challenges the shareholder approval of the 2014 Equity Incentive Plan and subsequent stock option grants, alleging breach of fiduciary duties and corporate waste The company intends to defend the action vigorously but cannot estimate the costs or predict the outcome at this early stage - A shareholder derivative and class action lawsuit was filed on July 23, 2021, against the company, its directors, and certain officers[151](index=151&type=chunk) - The lawsuit contests the approval of the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan and subsequent stock option grants[151](index=151&type=chunk) - The company intends to defend the action vigorously but is currently unable to estimate costs or predict the outcome[151](index=151&type=chunk) [Risk Factors](index=32&type=section&id=Item%201A.%20Risk%20Factors) The company states there have been no material changes to the risk factors previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2020 It advises investors to carefully consider those risks, which could materially harm the business and cause the stock price to decline - There have been no material changes from the risk factors previously reported in the Annual Report on Form 10-K for the year ended December 31, 2020[153](index=153&type=chunk) [Other Required Disclosures](index=32&type=section&id=Other%20Required%20Disclosures) The company reports no unregistered sales of equity securities during the period Additionally, there were no defaults upon senior securities, no mine safety disclosures to report, and no other material information to disclose under Item 5 Item 6 provides an index of the exhibits filed with the report - There were no unregistered sales of the Company's equity securities during the six months ended June 30, 2021 (Item 2)[154](index=154&type=chunk) - The company reported no defaults upon senior securities (Item 3), no mine safety disclosures (Item 4), and no other information (Item 5)[155](index=155&type=chunk)[156](index=156&type=chunk)[157](index=157&type=chunk) - Item 6 lists the exhibits filed with the 10-Q report[158](index=158&type=chunk)[160](index=160&type=chunk)

Company Overview - PDS Biotech is a clinical-stage biotechnology company focused on developing immunotherapies based on the Versamune® platform[6] - As of March 31, 2021, PDS Biotech reported approximately $25 million in cash and is debt-free[7] - The company has approximately 15 employees and is headquartered in Florham Park, NJ[7] Versamune® Platform - Versamune®-based immunotherapies promote a powerful in vivo tumor-specific CD8+ killer T-cell response and generate a strong CD8+ T-cell memory response[5] - Preclinical studies showed that Versamune® induced a >10-fold number of highly potent T-cells and eradication of HPV-positive tumors after a single dose[44] - Phase 1 clinical trial data showed a >20-fold increase in circulating dual INF-γ & Granzyme-b inducing killer T-cells vs pre-treatment at day 14, leading to rapid clearance of lesions[47] Clinical Development Programs - PDS Biotech has three Phase 2 oncology clinical trials in progress with initial data releases expected in 2021[7] - PDS0101 is being developed in combination with Keytruda® for first-line treatment of recurrent/metastatic HPV-positive head and neck cancer, where KEYTRUDA (Standard of Care) has an ORR of ~20%[12, 64] - A Phase 2 trial is evaluating PDS0101 in combination with chemoradiation therapy in patients with advanced cervical cancer[68] - PDS0203, a Versamune®-based COVID-19 vaccine, is under development with funding of up to approximately $60 million from MCTI, Brazil to support Phase 1-3 clinical development and manufacturing scale-up[87]

Financial Data and Key Metrics Changes - For Q1 2021, the company reported a loss from operations of approximately $3 million, an improvement from a loss of approximately $4 million in Q1 2020, resulting in a net loss of $0.14 per share compared to $0.39 per share in the previous year [38] - Research and development expenses decreased to approximately $1.4 million in Q1 2021 from $2 million in Q1 2020, a reduction of about 28% [39] - General and administrative expenses also saw a decline, totaling approximately $1.6 million in Q1 2021 compared to approximately $2.1 million in Q1 2020, a decrease of about 19% [39] - The company started 2021 with approximately $28.8 million in cash and ended the quarter with approximately $25 million after using about $3.8 million in operations [40] Business Line Data and Key Metrics Changes - The company is advancing its Versamune-based immuno-oncology pipeline, particularly focusing on the lead oncology candidate PDS0101, which is currently in three Phase II clinical trials for advanced HPV-associated cancers [7][8] - The ongoing National Cancer Institute-led trial of PDS0101 achieved a preliminary efficacy benchmark with at least 40% of patients showing tumor regression, which is a significant improvement over standard treatments [9][10] Market Data and Key Metrics Changes - The HPV cancer market is substantial, with approximately 43,000 new cases annually in the U.S., and the incidence of HPV-associated cancers continues to rise, particularly head and neck cancers [21] - The company anticipates that the ongoing clinical trials will provide critical data to support the commercialization of PDS0101 in various HPV-associated cancers [20] Company Strategy and Development Direction - The company aims to position PDS0101 for rapid market penetration by evaluating it in all HPV-associated cancers and combining it with standard-of-care treatments [20] - The strategy includes maintaining low cash burn rates while advancing oncology development programs and leveraging non-dilutive financing for infectious disease products [40] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of the Versamune platform in oncology, with upcoming data presentations expected to validate its efficacy [42][71] - The company is focused on building partnerships to expand its immuno-oncology pipeline, leveraging proof-of-concept data from ongoing trials [68][69] Other Important Information - The company announced a commitment of approximately $60 million from the Brazilian Ministry of Science, Technology and Innovation to support the clinical development of a Versamune-based COVID-19 vaccine [25] - The company is also developing a universal flu vaccine in collaboration with the University of Kentucky, with preclinical studies underway [26] Q&A Session Summary Question: Importance of T-cells and geographical reach of the COVID program - Management highlighted the significance of T-cells in robust immunity against COVID-19 and the potential for broader geographical reach as data becomes available [45][46] Question: Data expectations for PDS0101 - Management indicated that data from approximately 20 to 25 patients would be available soon, with an abstract to be released by ASCO on May 19 [51][52] Question: Regulatory considerations for VERSATILE study - Management anticipates a randomized Phase II trial design for registration, focusing on objective response rates and duration of response as key endpoints [62] Question: Gating factors for COVID-19 trial initiation - The completion of the manufacturing process by Farmacore is a key gating item for initiating human clinical trials in Brazil [66] Question: Potential for partnerships with third-party companies - Management acknowledged the potential for partnerships to develop additional immuno-oncology products using the Versamune platform [68][69]

PART I — FINANCIAL INFORMATION This section provides the unaudited condensed consolidated financial statements and management's discussion and analysis for the reporting period [ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)](index=4&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) This section presents the unaudited condensed consolidated financial statements for PDS Biotechnology Corporation, including the balance sheets, statements of operations and comprehensive loss, changes in stockholders' equity, and cash flows, along with detailed notes explaining the company's operations, accounting policies, liquidity, and other financial disclosures for the quarter ended March 31, 2021 [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This section presents the company's financial position, including assets, liabilities, and equity, as of the specified dates Condensed Consolidated Balance Sheet Highlights (in USD) | Metric | March 31, 2021 | December 31, 2020 | Change (Absolute) | | :-------------------------------- | :------------- | :---------------- | :---------------- | | Cash and cash equivalents | $25,037,374 | $28,839,565 | $(3,802,191) | | Total current assets | $27,256,888 | $30,337,230 | $(3,080,342) | | Total assets | $27,761,665 | $30,890,379 | $(3,128,714) | | Total current liabilities | $2,929,047 | $3,270,450 | $(341,403) | | Total Liabilities | $3,387,338 | $3,760,803 | $(373,465) | | Total stockholders' equity | $24,374,327 | $27,129,576 | $(2,755,249) | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) This section details the company's financial performance, including revenues, expenses, and net loss, for the specified periods Condensed Consolidated Statements of Operations and Comprehensive Loss (Three Months Ended March 31, in USD) | Metric | 2021 | 2020 | Change (Absolute) | Change (%) | | :------------------------------------ | :----------- | :----------- | :---------------- | :--------- | | Research and development expenses | $1,413,057 | $1,971,679 | $(558,622) | -28.3% | | General and administrative expenses | $1,636,216 | $2,060,148 | $(423,932) | -20.6% | | Total operating expenses | $3,049,273 | $4,031,827 | $(982,554) | -24.4% | | Loss from operations | $(3,049,273) | $(4,031,827) | $982,554 | -24.4% | | Interest income | $655 | $46,419 | $(45,764) | -98.6% | | Net loss and comprehensive loss | $(3,048,618) | $(3,985,408) | $936,790 | -23.5% | | Net loss per share, basic | $(0.14) | $(0.39) | $0.25 | -64.1% | | Weighted average common shares outstanding, basic | 22,263,838 | 10,314,761 | 11,949,077 | 115.8% | [Condensed Consolidated Statements of Changes in Stockholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Stockholders'%20Equity) This section outlines the changes in the company's equity accounts, such as stock-based compensation and net loss, over the reporting period Changes in Stockholders' Equity (Three Months Ended March 31, in USD) | Metric | March 31, 2021 | December 31, 2020 | | :-------------------------------- | :------------- | :---------------- | | Balance - December 31, 2020 | N/A | $27,129,576 | | Stock-based compensation expense | $257,622 | N/A | | Issuance of common stock from 401K match | $35,747 | N/A | | Net loss | $(3,048,618) | N/A | | Balance - March 31, 2021 | $24,374,327 | N/A | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) This section reports the cash inflows and outflows from operating, investing, and financing activities for the specified periods Condensed Consolidated Statements of Cash Flows (Three Months Ended March 31, in USD) | Metric | 2021 | 2020 | | :------------------------------------ | :----------- | :----------- | | Net loss | $(3,048,618) | $(3,985,408) | | Stock-based compensation expense | $257,622 | $124,992 | | Net cash used in operating activities | $(3,802,191) | $(3,164,394) | | Net cash provided by financing activities | $0 | $12,040,461 | | Net increase (decrease) in cash and cash equivalents | $(3,802,191) | $8,876,067 | | Cash and cash equivalents at end of period | $25,037,374 | $21,037,806 | [Notes to Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) This section provides detailed explanations and additional information supporting the condensed consolidated financial statements [Note 1 – Nature of Operations](index=8&type=section&id=Note%201%20%E2%80%93%20Nature%20of%20Operations) PDS Biotechnology Corporation is a clinical-stage immunotherapy company developing cancer immunotherapies and infectious disease vaccines using its proprietary Versamune® platform. The COVID-19 pandemic has caused clinical trial delays but also led to an expanded infectious disease pipeline, including a COVID-19 vaccine candidate (PDS0203) with a significant funding commitment from Brazil * PDS Biotechnology is a clinical-stage immunotherapy company focused on developing cancer immunotherapies and infectious disease vaccines, leveraging its proprietary **Versamune® T-cell activating platform**[20](index=20&type=chunk) * The COVID-19 pandemic caused delays in **two of the three PDS0101 clinical trials** for cancer indications, impacting clinical trial operations and patient enrollment[24](index=24&type=chunk) * The company has expanded its infectious disease pipeline to include PDS0203, a Versamune®-based COVID-19 vaccine, with a consortium in Brazil receiving a commitment of up to **US$60 million** for its clinical development and commercialization[27](index=27&type=chunk) [Note 2 – Summary of Significant Accounting Policies](index=9&type=section&id=Note%202%20%E2%80%93%20Summary%20of%20Significant%20Accounting%20Policies) This note outlines the company's significant accounting policies, including the preparation of unaudited interim financial statements under U.S. GAAP, the use of estimates, and the expensing of research and development costs and stock-based compensation. It also highlights key operational risks and uncertainties * Unaudited interim financial statements are prepared in accordance with **U.S. GAAP and SEC requirements** for interim reporting, with certain footnotes condensed or omitted[28](index=28&type=chunk) * The company's operations are subject to significant risks and uncertainties, including clinical and regulatory development, cash resource preservation, intellectual property, competition, and the impact of health epidemics like COVID-19[30](index=30&type=chunk) * Research and development costs are expensed as incurred, and stock-based compensation is recognized as an expense based on grant date fair values using the **Black-Scholes option-pricing model**[33](index=33&type=chunk)[36](index=36&type=chunk) [Note 3 – Liquidity](index=11&type=section&id=Note%203%20%E2%80%93%20Liquidity) As of March 31, 2021, the company held $25.0 million in cash and cash equivalents. It has historically funded operations through equity offerings, raising approximately $11.9 million and $17.1 million net in 2020, and has $81.0 million available under a shelf registration. Management believes current funds are sufficient for at least 12 months, but plans to seek additional financing through equity/debt or partnerships * Cash and cash equivalents as of March 31, 2021, totaled **$25.0 million**[40](index=40&type=chunk) * The company completed an underwritten public offering in February 2020, receiving net proceeds of approximately **$11.9 million**[42](index=42&type=chunk) * In August 2020, the company sold common stock under a shelf registration, receiving net proceeds of approximately **$17.1 million**, with approximately **$81.0 million** of Shelf Securities remaining available[43](index=43&type=chunk) * Management believes current cash resources are sufficient to continue operations and research and development programs for at least **12 months** from the report date[45](index=45&type=chunk) * Future funding plans include equity and/or debt financings, government funding programs, and potential partnerships, with the understanding that additional financing may not be available on favorable terms[46](index=46&type=chunk) [Note 4 – Fair Value of Financial Instruments](index=12&type=section&id=Note%204%20%E2%80%93%20Fair%20Value%20of%20Financial%20Instruments) This note confirms that there were no transfers among fair value hierarchy levels during 2021 or 2020, and all cash and cash equivalents are classified as Level 1 assets, indicating readily observable market prices * No transfers among Levels 1, 2, or 3 of the fair value hierarchy occurred during **2021 or 2020**[47](index=47&type=chunk) Fair Value Measurements of Cash and Cash Equivalents (in USD) | Date | Total | Level 1 (Quoted Prices in Active Markets) | | :---------------- | :----------- | :---------------------------------------- | | March 31, 2021 | $25,037,374 | $25,037,374 | | December 31, 2020 | $28,839,565 | $28,839,565 | [Note 5 – Leases](index=12&type=section&id=Note%205%20%E2%80%93%20Leases) The company entered into a sublease for office space in Florham Park, NJ, effective May 1, 2020, with a 40-month term, recognizing approximately $0.7 million in ROU assets and operating lease liabilities. It also maintains a month-to-month lease for research facilities. The note provides a maturity schedule for operating lease liabilities * The company entered into a sublease for approximately **11,200 square feet** of office space in Florham Park, NJ, commencing May 1, 2020, for a term of **forty months**[50](index=50&type=chunk) * Upon inception of the lease, approximately **$0.7 million** of a Right-of-Use (ROU) asset and operating lease liabilities were recognized[50](index=50&type=chunk) Maturity of Operating Lease Liability (Year Ended December 31, in USD) | Year | Amount | | :---------------------- | :------- | | 2021 (remaining 9 months) | $128,779 | | 2022 | $295,346 | | 2023 | $239,469 | | Total future minimum lease payments | $663,594 | | Less imputed interest | $(81,649) | | Total operating lease liability | $581,945 | [Note 6 – Accrued Expenses](index=13&type=section&id=Note%206%20%E2%80%93%20Accrued%20Expenses) Accrued expenses and other liabilities increased from $1,735,322 at December 31, 2020, to $1,854,795 at March 31, 2021, primarily driven by an increase in accrued compensation Accrued Expenses and Other Liabilities (in USD) | Category | March 31, 2021 | December 31, 2020 | | :------------------------------ | :------------- | :---------------- | | Accrued research and development costs | $23,900 | $204,780 | | Accrued professional fees | $320,266 | $219,822 | | Accrued compensation | $1,510,629 | $1,310,720 | | Total | $1,854,795 | $1,735,322 | [Note 7 – Stock-Based Compensation](index=13&type=section&id=Note%207%20%E2%80%93%20Stock-Based%20Compensation) The company recognized $257,622 in stock-based compensation expense for the three months ended March 31, 2021, an increase from $124,992 in the prior year. It details its equity compensation plans, including the 2018 Stock Incentive Plan and the 2019 Inducement Plan, and provides a summary of stock options outstanding and their valuation using the Black-Scholes model Stock-Based Compensation Expense (Three Months Ended March 31, in USD) | Category | 2021 | 2020 | | :-------------------------- | :------- | :------- | | Research and development | $60,385 | $52,684 | | General and administrative | $72,308 | $197,236 | | Total | $124,992 | $257,622 | * As of March 31, 2021, there were **1,899,197 stock options outstanding** with a weighted average exercise price of **$10.40** and an aggregate intrinsic value of **$1,654,588**[60](index=60&type=chunk) * Approximately **$1,483,195** of unamortized stock option compensation expense is expected to be recognized over a remaining average vesting period of **3 years**[60](index=60&type=chunk) [Note 8 – Income Taxes](index=15&type=section&id=Note%208%20%E2%80%93%20Income%20Taxes) The company expects an operating loss for 2021 and has a full valuation allowance against its net deferred tax assets, resulting in no income tax benefit. It has no uncertain tax positions and its U.S. federal and state net operating losses are subject to examination from inception * A full valuation allowance was recorded against net deferred tax assets as of March 31, 2021, and December 31, 2020, due to realization uncertainties[61](index=61&type=chunk) * No income tax benefit was recorded for the three months ended March 31, 2021, and no uncertain income tax positions were identified[61](index=61&type=chunk)[63](index=63&type=chunk) [Note 9 – Commitments and Contingencies](index=15&type=section&id=Note%209%20%E2%80%93%20Commitments%20and%20Contingencies) This note details rent expenses for month-to-month arrangements not affected by ASC 842, showing a decrease in rent expense for the three months ended March 31, 2021, compared to the prior year Rent Expense for Month-to-Month Arrangements (Three Months Ended March 31, in USD) | Year | Amount | | :--- | :------- | | 2021 | $36,017 | | 2020 | $58,641 | [Note 10 – Retirement Plan](index=15&type=section&id=Note%2010%20%E2%80%93%20Retirement%20Plan) The company's 401(k) defined contribution plan received employer contributions of $35,747 for the three months ended March 31, 2021, an increase from $9,800 in the prior year 401(k) Employer Contributions (Three Months Ended March 31, in USD) | Year | Amount | | :--- | :------- | | 2021 | $35,747 | | 2020 | $9,800 | [Note 11 – Subsequent Events](index=15&type=section&id=Note%2011%20%E2%80%93%20Subsequent%20Events) Subsequent events have been evaluated through the date the financial statements were issued, with no material events requiring disclosure * Subsequent events were evaluated through the date the financial statements were issued[66](index=66&type=chunk) [ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS](index=16&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section provides management's perspective on the company's financial condition and results of operations for the three months ended March 31, 2021, compared to 2020. It covers the business overview, financial performance, liquidity, and the impact of COVID-19, emphasizing the company's focus on clinical-stage immunotherapy development and its funding strategies [Company Overview](index=17&type=section&id=Company%20Overview) PDS Biotechnology is a clinical-stage immunotherapy company developing cancer immunotherapies and infectious disease vaccine candidates using its proprietary Versamune® T-cell activating platform * PDS Biotechnology is a clinical-stage immunotherapy company developing cancer immunotherapies and infectious disease vaccine candidates using its proprietary **Versamune® T-cell activating platform**[72](index=72&type=chunk) * PDS0101 is in Phase 2 clinical trials for recurrent/metastatic head and neck cancer (in combination with KEYTRUDA®), advanced HPV-associated malignancies (with M7824 and NHS-IL12), and locally advanced cervical cancer (with chemo-radiotherapy)[75](index=75&type=chunk)[77](index=77&type=chunk)[80](index=80&type=chunk) * The company is developing PDS0203, a Versamune®-based COVID-19 vaccine, with a consortium in Brazil that has secured a commitment of up to **US$60 million** for clinical development and commercialization[85](index=85&type=chunk)[86](index=86&type=chunk) * Other Versamune®-based therapies in the pipeline include PDS0102 (TARP antigens), PDS0103 (MUC-1 antigens), PDS0104 (TRP-2 and melanoma antigens), PDS0202 (universal influenza vaccine), and PDS0201 (tuberculosis immunotherapy)[81](index=81&type=chunk)[82](index=82&type=chunk)[83](index=83&type=chunk)[84](index=84&type=chunk)[89](index=89&type=chunk) [Key Components of Our Statement of Operations](index=20&type=section&id=Key%20Components%20of%20Our%20Statement%20of%20Operations) This section outlines the key components of the company's statement of operations, including revenue generation, research and development expenses, and the inherent uncertainties in pharmaceutical product development * The company has not generated any revenues from commercial product sales and expects future revenue from research and development payments, license fees, and milestone payments[93](index=93&type=chunk) * Research and development expenses are expensed as incurred and are expected to increase significantly as the company advances its Versamune®-based immuno-oncology candidates through clinical trials and prepares for potential commercial launch[94](index=94&type=chunk)[95](index=95&type=chunk) * Due to the numerous risks and uncertainties in pharmaceutical product development, the company is unable to estimate the exact duration and completion costs of its R&D projects or when it will generate revenue from product commercialization[96](index=96&type=chunk) [Results of Operations](index=21&type=section&id=Results%20of%20Operations) This section presents a comparative analysis of the company's financial performance for the three months ended March 31, 2021, versus 2020, highlighting changes in operating expenses and net loss Results of Operations (Three Months Ended March 31, in thousands USD) | Metric | 2021 | 2020 | Change ($) | Change (%) | | :-------------------------------- | :--- | :--- | :--------- | :--------- | | Research and development expenses | $1,413 | $1,971 | $(559) | -28% | | General and administrative expenses | $1,636 | $2,060 | $(424) | -21% | | Total operating expenses | $3,049 | $4,031 | $(983) | -24% | | Loss from operations | $(3,049) | $(4,031) | $983 | -24% | | Interest income, net | $1 | $46 | $(45) | -98% | | Net loss and comprehensive loss | $(3,048) | $(3,985) | $936 | -23% | * The decrease in research and development expenses by **$0.6 million** was primarily due to a **$0.3 million** decrease in professional services and a **$0.3 million** decrease in clinical studies[98](index=98&type=chunk) * General and administrative expenses decreased by **$0.5 million**, mainly due to a **$0.7 million** decrease in professional services (including legal fees), partially offset by a **$0.2 million** increase in personnel costs[99](index=99&type=chunk) [Liquidity and Capital Resources](index=21&type=section&id=Liquidity%20and%20Capital%20Resources) This section details the company's cash position, historical fundraising activities, and future funding strategies, emphasizing management's belief in sufficient current resources for at least 12 months * As of March 31, 2021, the company had **$25.0 million** in cash and cash equivalents[104](index=104&type=chunk) * In February 2020, the company completed a public offering, raising approximately **$11.9 million** in net proceeds[102](index=102&type=chunk) * In August 2020, the company sold common stock under a shelf registration, raising approximately **$17.1 million** in net proceeds, with approximately **$81.0 million** of Shelf Securities remaining available for future sale[103](index=103&type=chunk) * Management believes that existing cash resources are sufficient to continue operations and research and development programs for at least **12 months** from the date of the report[105](index=105&type=chunk) * The company plans to fund future operations through equity and/or debt financings, government funding programs, and potential partnerships, acknowledging the risk of dilution or restrictive covenants[106](index=106&type=chunk) [Cash Flows](index=22&type=section&id=Cash%20Flows) This section summarizes the company's cash flow activities for the three months ended March 31, comparing 2021 to 2020, and highlighting changes in operating and financing cash flows Summary of Cash Flows (Three Months Ended March 31, in thousands USD) | Category | 2021 | 2020 | | :------------------------------------ | :----- | :----- | | Net cash used in operating activities | $(3,802) | $(3,164) | | Net cash provided by financing activities | $0 | $12,040 | | Net increase (decrease) in cash and cash equivalents | $(3,802) | $8,876 | * The increase in net cash used in operating activities by **$0.6 million** in Q1 2021 was primarily due to an increase in prepaid expenses related to the Syneos CRO contract[108](index=108&type=chunk) * Net cash provided by financing activities in Q1 2020 was **$12.0 million**, primarily from the issuance of common stock, with no such activities in Q1 2021[109](index=109&type=chunk) [Operating Capital Requirements](index=23&type=section&id=Operating%20Capital%20Requirements) This section discusses the company's ongoing need for substantial additional funding to support its operations and product development, acknowledging the uncertainties in securing such financing * The company has not generated product revenue and anticipates continued and increasing losses as it develops and seeks regulatory approvals for its product candidates[110](index=110&type=chunk) * Substantial additional funding will be required for continuing operations, and the ability to secure such funding on acceptable terms is uncertain[110](index=110&type=chunk)[106](index=106&type=chunk) * Future funding requirements depend on factors such as the timing and costs of clinical trials, regulatory approvals, intellectual property costs, and commercialization efforts[112](index=112&type=chunk) [Contractual Obligations and Commitments](index=24&type=section&id=Contractual%20Obligations%20and%20Commitments) This section outlines the company's contractual obligations, primarily operating lease liabilities, and confirms the absence of material non-cancelable purchase commitments Contractual Obligations as of March 31, 2021 (in USD) | Obligation | Total | Less than 1 Year | 1-3 Years | 3-5 Years | More than 5 Years | | :------------------------ | :-------- | :--------------- | :-------- | :-------- | :---------------- | | Operating lease obligations | $581,945 | $123,654 | $458,291 | $0 | $0 | | Total contractual obligations | $581,945 | $123,654 | $458,291 | $0 | $0 | * The company has no material non-cancelable purchase commitments with service providers[115](index=115&type=chunk) [Critical Accounting Policies and Estimates](index=24&type=section&id=Critical%20Accounting%20Policies%20and%20Estimates) This section affirms that the financial statements are prepared under U.S. GAAP, requiring management estimates, and notes no material changes to critical accounting policies since the prior annual report * The financial statements are prepared in accordance with U.S. GAAP, requiring management to make estimates and assumptions that affect reported amounts[116](index=116&type=chunk) * There have been no material changes to the company's critical accounting policies and estimates during the three months ended March 31, 2021, from those disclosed in its Annual Report on Form 10-K for the year ended December 31, 2020[117](index=117&type=chunk) [Impact of the CARES Act](index=24&type=section&id=Impact%20of%20the%20CARES%20Act) This section states that the company evaluated the CARES Act and does not anticipate any material financial impact or significant changes to its internal controls * The company evaluated the CARES Act and does not expect any material cash benefit or significant impact on its financial statements or internal controls over financial reporting[118](index=118&type=chunk) [Operations and Liquidity (COVID-19 Impact)](index=24&type=section&id=Operations%20and%20Liquidity%20(COVID-19%20Impact)) This section addresses the significant disruptions and uncertainties caused by the COVID-19 pandemic, including clinical trial delays, while highlighting the company's resilient cash position and expanded infectious disease pipeline * The COVID-19 pandemic has caused significant disruption and uncertainty, potentially affecting the company's liquidity and operations, including delays in clinical trial enrollment[119](index=119&type=chunk)[121](index=121&type=chunk) * Despite the uncertainty, the company believes its current cash reserves position it well to manage through the crisis[122](index=122&type=chunk) * The company has expanded its infectious disease pipeline to include a COVID-19 vaccine candidate (PDS0203) due to renewed interest in related technologies[123](index=123&type=chunk) [Off-Balance Sheet Arrangements](index=25&type=section&id=Off-Balance%20Sheet%20Arrangements) This section confirms that the company had no off-balance sheet arrangements during the reported periods and currently has none * The company did not have any off-balance sheet arrangements during the periods presented and does not currently have any[124](index=124&type=chunk) [Smaller Reporting Company](index=25&type=section&id=Smaller%20Reporting%20Company) This section clarifies the company's reporting status, noting it is no longer an "emerging growth company" but remains a "smaller reporting company" and will utilize available disclosure exemptions * As of January 1, 2021, the company is no longer an "emerging growth company" but remains a "smaller reporting company" and intends to rely on available disclosure exemptions[125](index=125&type=chunk) [ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK](index=26&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risk exposure is interest rate sensitivity. However, due to the short-term maturities and low-risk profile of its cash equivalents, a significant change in interest rates is not expected to materially affect their fair market value * The company's primary exposure to market risk is **interest rate sensitivity**[126](index=126&type=chunk) * As of March 31, 2021, cash equivalents of **$25.0 million** were held in a non-interest-bearing money operating account and an institutional U.S. Treasury money market fund[126](index=126&type=chunk) * Due to the short-term maturities and low-risk profile of investments, an immediate **100 basis point change** in interest rates is not expected to have a material effect on the fair market value of cash equivalents[126](index=126&type=chunk) [ITEM 4. CONTROLS AND PROCEDURES](index=26&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including the Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the company's disclosure controls and procedures as of March 31, 2021, concluding they were effective. No material changes in internal control over financial reporting were identified during the quarter * Disclosure controls and procedures were evaluated by management, including the CEO and CFO, and concluded to be **effective** as of March 31, 2021[127](index=127&type=chunk) * No changes in internal control over financial reporting that materially affected, or are reasonably likely to materially affect, internal control over financial reporting occurred during the quarter ended March 31, 2021[128](index=128&type=chunk) PART II — OTHER INFORMATION This section includes disclosures on legal proceedings, risk factors, equity sales, and other miscellaneous information [ITEM 1. LEGAL PROCEEDINGS](index=27&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently involved in any legal proceedings that, in management's opinion, would have a material adverse effect on its results of operations or financial position * The company is not currently a party to any legal proceedings that would have a material adverse effect on its results of operations or financial position[130](index=130&type=chunk) [ITEM 1A. RISK FACTORS](index=27&type=section&id=Item%201A.%20Risk%20Factors) There have been no material changes to the risk factors previously reported in the Annual Report on Form 10-K for December 31, 2020. The company reiterates that an investment involves a high degree of risk, and investors should carefully consider all information * There have been **no material changes** from the risk factors previously reported in the Annual Report on Form 10-K for the year ended December 31, 2020[131](index=131&type=chunk) * Any investment in the company's business involves a **high degree of risk**, and investors should carefully consider all information[131](index=131&type=chunk) [ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS](index=27&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) There were no unregistered sales of the company's equity securities during the three months ended March 31, 2021 * No unregistered sales of the company's equity securities occurred during the three months ended March 31, 2021[132](index=132&type=chunk) [ITEM 3. DEFAULTS UPON SENIOR SECURITIES](index=27&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities during the period * The company reported **no defaults** upon senior securities[133](index=133&type=chunk) [ITEM 4. MINE SAFETY DISCLOSURES](index=27&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company's operations * This item is **not applicable** to the company[134](index=134&type=chunk) [ITEM 5. OTHER INFORMATION](index=27&type=section&id=Item%205.%20Other%20Information) The company reported no other information for this period * No other information was reported[135](index=135&type=chunk) [ITEM 6. EXHIBITS](index=27&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including certifications, XBRL documents, and other required filings * The section lists exhibits filed with the Form 10-Q, including certifications of the Principal Executive Officer and Principal Financial Officer, and XBRL documents[138](index=138&type=chunk) EXHIBIT INDEX This section provides a comprehensive list of all documents filed as exhibits to the current report * The Exhibit Index provides a detailed list of all documents filed as exhibits to the Form 10-Q, including various certifications and XBRL-related files[138](index=138&type=chunk) SIGNATURES This section formally attests to the accuracy and completeness of the report by authorized corporate officers * The report was signed on **May 13, 2021**, by Frank Bedu-Addo, President and Chief Executive Officer, and Seth Van Voorhees, Chief Financial Officer, as duly authorized representatives of PDS Biotechnology Corporation[142](index=142&type=chunk)

Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________to ________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission file number 001-37568 PDS Biotechnology Corporation (Exact name of registrant as specified in its charter) Delaware 26-4231384 (State or other juri ...

Financial Data and Key Metrics Changes - For fiscal year 2020, the company's loss from operations was approximately $14.9 million, a decrease from a loss of approximately $21 million in 2019, indicating improved operational efficiency [39] - The net loss for fiscal 2020 was approximately $14.9 million or $0.89 per share, compared to a net loss of $7 million or $1.44 per share in 2019, reflecting a significant reduction in losses [40] - Research and development expenses increased to approximately $7.9 million in 2020 from $6.1 million in 2019, marking a 30% increase primarily due to higher Versamune-related expenditures [41] - General and administrative expenses decreased to approximately $7 million in 2020 from approximately $11 million in 2019, a reduction of about 37% [41] - The company ended 2020 with a cash balance of approximately $29 million after raising $30 million from equity issuance [41] Business Line Data and Key Metrics Changes - The oncology pipeline saw significant advancements with three ongoing Phase 2 clinical trials for PDS0101, which is being developed for advanced HPV-associated cancers [6][10] - The COVID-19 program, PDS0203, made progress with a funding commitment of approximately $60 million from the Brazilian government to support clinical development and commercialization [22][42] Market Data and Key Metrics Changes - The HPV cancer market is expected to remain robust for decades, with about 43,000 new incidences of HPV-associated cancers annually in the U.S. alone [18] - The Brazilian market represents a potential multibillion-dollar revenue opportunity based on its population and reported COVID-19 vaccine pricing [42][29] Company Strategy and Development Direction - The company aims to combine PDS0101 with state-of-the-art treatments to enhance clinical outcomes for HPV-associated cancer patients, positioning itself for rapid market penetration post-approval [10][18] - The strategy includes leveraging partnerships with leading institutions like the National Cancer Institute and M.D. Anderson Cancer Center to validate the Versamune platform [38] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about 2021, highlighting multiple ongoing clinical trials and the anticipated initiation of trials for the second-generation COVID-19 vaccine [63] - The company believes that successful clinical trials will validate the Versamune platform's potential in both oncology and infectious diseases [44] Other Important Information - The company has initiated collaborations with Brazilian partners for the development of a COVID-19 vaccine, expanding its consortium to include leading pharmaceutical companies [8][23] - The company retains 100% ownership of PDS0101 and other Versamune-based products, which is crucial for its strategic positioning in the market [10] Q&A Session Summary Question: Can you provide more perspective on the NCI study's patient population and the contributions of each therapy? - Management clarified that the study targets patients with HPV-related recurrent metastatic disease, including various cancer types, and emphasized the importance of understanding the contributions of each therapy in combination treatments [49][50] Question: What is the regulatory process for Brazil and its impact on commercialization across Latin America? - Management explained that the regulatory process in Brazil is similar to the U.S. FDA, with frequent communication during trials, and noted that approval in Brazil could facilitate quicker uptake in other Latin American countries [59][60]

CORPORATE OVERVIEW MARCH 2021 Frank Bedu-Addo Ph.D. President & CEO 6 Nasdaq: PDSB Developing powerful, safe, versatile immunotherapies Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, business prospects, strategies and plans, including but not limited to statements regarding anticipated pre-clinical and clinical drug development activities and timelines and market opportunities. All statements other than state ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number 001-37568 PDS Biotechnology Corporation (Exact name of registrant as specified in its charter) Delaware 26-4231384 (S ...

PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2020 Earnings Conference Call November 12, 2020 8:00 AM ET Company Participants Deanne Randolph - Investor Relations Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Michael King - Interim Chief Financial Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Ahu Demir - Noble Capital Jim Malloy - Alliance Global Partners Operator Greetings. Welcome to PDS Biotechnology's Third Quarter 2020 Earnings Call. At this time ...